TY  - JOUR
AU  - Derigs, Patrick
AU  - Bethge, Wolfgang A
AU  - Krämer, Isabelle
AU  - Holtick, Udo
AU  - von Tresckow, Bastian
AU  - Ayuk, Francis
AU  - Penack, Olaf
AU  - Vucinic, Vladan
AU  - von Bonin, Malte
AU  - Baldus, Claudia
AU  - Mougiakakos, Dimitrios
AU  - Wulf, Gerald
AU  - Schnetzke, Ulf
AU  - Stelljes, Matthias
AU  - Fante, Matthias
AU  - Schroers, Roland
AU  - Kroeger, Nicolaus
AU  - Dreger, Peter
TI  - Long-Term Survivors After Failure of CAR-T Cell Therapy for Large B-Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A GLA/DRST Analysis.
JO  - Transplantation and cellular therapy
VL  - 29
IS  - 12
SN  - 2666-6375
CY  - [Amsterdam]
PB  - Elsevier B. V.
M1  - DKFZ-2023-01879
SP  - 750-756
PY  - 2023
N1  - 2023 Dec;29(12):750-756
AB  - The outcome of patients with large B-cell lymphoma (LBCL) who relapse or progress after CD19-directed CAR-T cell therapy administered as salvage therapy beyond the second treatment line is poor. However, a minority of patients become long-term survivors despite CAR-T failure. The German Lymphoma Alliance (GLA) has proposed a hierarchical management algorithm for CAR-T failure in LBCL, aiming at allogeneic hematopoietic cell transplantation (alloHCT) as definite therapy in eligible patients.The purpose of this study was to investigate characteristics, relapse patterns and management strategies in long-term survivors after CAR-T failure with particular focus on feasibility and outcome of alloHCT.Retrospective analysis of all evaluable patients with relapse/progression event (REL) observed in a previous reported GLA sample (Bethge et al, Blood 2022) between November 2018 and May 2021.REL occurred in 214 of 356 patients (60
KW  - Allogeneic Hematopoietic Cell Transplantation (Other)
KW  - CAR-T (Other)
KW  - Lymphoma (Other)
KW  - Relapse (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37709204
DO  - DOI:10.1016/j.jtct.2023.09.008
UR  - https://inrepo02.dkfz.de/record/282877
ER  -